Neuroscience is a key part of Roche’s growth strategy, and it has just updated investors on how its pipeline could soon yield several breakthrough drugs.
The company covered a broad range of candidates in its neuroscience investor day on 11 March, but presented new data...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?